Insider Stock Buyers At Aclaris Therapeutics Recouped Some Losses This Week

Insiders who bought US$192.9k worth of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) stock in the last year recovered part of their losses as the stock rose by 16% last week. The purchase, however, has proven to be a pricey bet, with losses currently totalling US$147k.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

See our latest analysis for Aclaris Therapeutics

The Last 12 Months Of Insider Transactions At Aclaris Therapeutics

The Chief Business Officer James Loerop made the biggest insider purchase in the last 12 months. That single transaction was for US$100k worth of shares at a price of US$6.80 each. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$1.19). It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

While Aclaris Therapeutics insiders bought shares during the last year, they didn't sell. They paid about US$4.98 on average. I'd consider this a positive as it suggests insiders see value at around the current price. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

Aclaris Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Insider Ownership

Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data suggests Aclaris Therapeutics insiders own 2.6% of the company, worth about US$2.2m. We prefer to see high levels of insider ownership.

So What Does This Data Suggest About Aclaris Therapeutics Insiders?

It doesn't really mean much that no insider has traded Aclaris Therapeutics shares in the last quarter. However, our analysis of transactions over the last year is heartening. The transactions are fine but it'd be more encouraging if Aclaris Therapeutics insiders bought more shares in the company. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. In terms of investment risks, we've identified 2 warning signs with Aclaris Therapeutics and understanding these should be part of your investment process.

But note: Aclaris Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com